Korean Pharma Voluntarily Withdraws Phase 2 Clinical Trial Application for Elderly Sarcopenia Patients

[Asia Economy Reporter Oh Ju-yeon] Korea Pharma announced on the 10th that it has voluntarily withdrawn its application for a multicenter, dose-finding, Phase 2 clinical trial plan to evaluate the efficacy and safety of repeated administration of KP203 in elderly patients with sarcopenia.

The company stated the reason for the voluntary withdrawal as follows: "We judged that the time required to conduct tests and prepare materials to submit supplementary data requested by the Ministry of Food and Drug Safety is excessive, making it difficult to submit the supplementary data within the deadline."